Bladder Control After 40: How The Peptide Vesilute is Changing the Conversation!
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
-
Lu par :
-
De :
À propos de ce contenu audio
- Join our free community, The Women’s Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663
- Go to https://thepeptique.com/ to get all your research peptides .As a loyal listener use the discount code POD15 to get 15% off the entire line of products.
- Have questions? Feel free to reach out to me: tarawest@westwellnessatx.com
- Want the free peptide guide? Email me tarawest@westwellnessatx.com and comment Guide and I'll shoot it right over!
- Follow me on instagram AND TikTOk @westwellnessatx
- Stay in touch add your email to the list ! https://form.jotform.com/25336471779006
In this episode, we take a deep dive into the research behind Vesilute — a short peptide bioregulator studied for bladder and urogenital tissue support. We explore clinical findings from Eastern European studies, including reported reductions in urinary frequency and urgency, improvements in bladder capacity, and sustained benefits beyond treatment cycles. We also discuss aging animal data showing improvements in epithelial integrity, microcirculation, connective tissue density, and inflammatory markers.
Most importantly, we connect the science to real-life peri-menopause and menopause changes,including collagen decline, reduced blood flow, tissue thinning, and increased urgency.
This episode breaks down what the research suggests, how Vesilute differs from hormonal therapy and traditional bladder medications, and why structural tissue signaling may matter for long-term pelvic longevity.
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !